Abstract
Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 1003-1013 |
Number of pages | 11 |
Journal | Journal of the American Academy of Dermatology |
Volume | 69 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2013 |
Externally published | Yes |
Keywords
- biologics
- cyclosporine
- immunosuppressive therapy
- inactivated vaccine
- live vaccine
- methotrexate
- vaccine administration
- vaccine counseling
ASJC Scopus subject areas
- Dermatology